Journals / Fırat Tıp Dergisi / 2018 / Cilt: 23 - Sayı: 0

Medical Treatment of Obesity

Obezitenin Medikal Tedavisi

Pages
72–77
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

If safety and long-term effectiveness of these drugs will be proven, promising changes in obesity management are expected.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Obesity is a complex and multifactorial disease.
📊
Key Findings & Data:Together with the increasing prevalence of obesity worldwide among children and adolescents, the need for effective and sustainable treatment has been increasing.
💡
Conclusion & Impact:If safety and long-term effectiveness of these drugs will be proven, promising changes in obesity management are expected.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Obesity is a complex and multifactorial disease. Together with the increasing prevalence of obesity worldwide among children and adolescents, the need for effective and sustainable treatment has been increasing. An important part of obesity is related to morbidity. Main part of the management of obesity is lifestyle change such as exercise and medical nutrition therapy. Pharmacological treatments can be used, if lifestyle modification recom-mendations are inadequate. Orlistat is not solely sufficient among the current medical treatments. Although the development of new drugs is difficult due to complexity of systemic pharmacotherapies and variables such as ethnicity and age, several drugs are still under development. If safety and long-term effectiveness of these drugs will be proven, promising changes in obesity management are expected.

Özet

Obezite kompleks ve multifaktöriyel bir hastalıktır. Obezite prevalansı dünya çapında çocuk ve ergenler arasında yükselirken, etkili ve sürdürülebilir tedavilere olan talep artmaktadır. Obezitenin önemli bir kısmı morbiditeyle ilişkilidir. Obezitenin tedavisinde temel olan tıbbi beslenme tedavisi, egzersiz gibi yaşam tarzı değişikliğidir. Yaşam tarzı değişikliği önerileri yetersiz kaldığında farmakolojik tedaviler kullanılabilir. Şu anki medikal tedavilerde Orlistat tümüyle yeterli değildir. Obezite tedavisinde, yeni ilaçların geliştirilmesi hem sistemik farmakoterapinin karmaşıklığı hem de etnik köken ve yaş gibi değişkenler nedeniyle zor olsada çalışması devam eden ilaçlar mevcuttur. Güvenlik ve uzun vadeli etkinlikleri ispat edilirse, obezite yönetiminde umut verici değişiklikler beklenmektedir.

🔖

Cite This Article

EVREN, B., TOPALOĞLU, Ö. (2018). Medical Treatment of Obesity. Fırat Tıp Dergisi, Cilt: 23 - Sayı: 0, 72–77. https://ajindex.com/articles/223552

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Türkiye Endokrinoloji ve Metabolizma Derneği, (2018). Obezite Tanı ve Tedavi Kılavuzu ISBN: 978-605-4011-31-5. 80-6. Department of Health–Public Health. Obesity general information, 2011. www.dh.gov.uk/en/Publichealth/Obesity/DH_078098. [Accessed 9 February 2012].
  2. Hurt RT, Frazier TH, Mc Clave SA, et al. Obe-sity epidemic. J Parenter Enteral Nutr 2011; 35: 4-13.
  3. Bray GA, Tartaglia LA, Bray GA, et al. Medi-cinal strategies in the treatment of obesity. Na-ture 2000; 404: 672. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123-8. US FDA. Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events.2010. http://www.fda.gov/safety/medwatch/safety in-formation/safety alerts for human medical pro-ducts/ucm228830.htm. Padwal RS, Rucker D, Li SK et al. Long-term pharmacotherapy for obesity and overweight (Review). Cochrane Database of Systematic Reviews 2003, CD004094. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-42.
  4. Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, or-listat, on serum lipids and lipoproteins in pati-ents with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46: 405-10.
  5. Singh A, Sarkar SR, Gaber LW, Perazella MA. Acute oxalate nephropathy associated with or-listat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007; 49: 153-7.
  6. Smith SR, Prosser WA, Donahue DJ, et al. APD356004 Study Group. Lorcaserin (APD356), a selective 5-HT(2C) agonist, redu-ces body weight in obese men and women. Obe-sity (Silver Spring) 2009; 17: 494-503.
  7. Smith SR, Weissman NJ, Anderson CM, et al; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight mana-gement. N Engl J Med 2010; 363: 245-56.
  8. Fidler MC, Sanchez M, Raether B, et al. BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96: 3067-77. FDA Highlights of Prescribing Information: BELVIQ (lorcaserin hydrochloride) tablets, for oral use. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf.
  9. Cercato C, Roizenblatt VA, Leança CC, et al. A randomized